Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8420619 | 1.00 | LTB4R (0.67) | LTB4RLTB4R2 | |
| SCHEMBL8564889 | 0.91 | LTB4R (0.68) | LTB4RLTB4R2 | |
| SCHEMBL8420032 | 0.86 | LTB4R (0.66) | LTB4RLTB4R2 | |
| SCHEMBL8418927 | 0.86 | LTB4R (0.81) | LTB4RLTB4R2 | |
| SCHEMBL8420120 | 0.86 | LTB4R (0.71) | LTB4RLTB4R2 | |
| SCHEMBL8573084 | 0.86 | LTB4R (0.81) | LTB4RLTB4R2 | |
| SCHEMBL8420323 | 0.86 | LTB4R (0.81) | LTB4RLTB4R2 | |
| SCHEMBL8418446 | 0.85 | LTB4R (0.65) | LTB4RLTB4R2 | |
| SCHEMBL8560587 | 0.82 | LTB4R (0.57) | LTB4RLTB4R2 | |
| SCHEMBL8422458 | 0.81 | LTB4R (0.60) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | claimed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | claimed |
| EP-0942903-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | Novartis AG (CH) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998013347-A1 | ARYL-SUBSTITUTED ACRYLAMIDES WITH LEUKOTRIENE B4 (LTB-4) RECEPTOR ANTAGONIST ACTIVITY | NOVARTIS AG (CH) | 1998-04-02 | — | — | WO | disclosed |